Premium
Investigation of microRNA‐146a and microRNA‐218 expression in cervical cancer
Author(s) -
Wang HongWei,
Terinate Paul,
Gao Youfang,
Kalra Krishan L.
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.lb316
Subject(s) - cervical cancer , microrna , cancer , medicine , biomarker , oncology , basal (medicine) , tissue microarray , pathology , biology , gene , genetics , insulin
Background Cervical cancer is the second most common cancer among women worldwide. However, information about miRNAs in cervical cancer remains limited. Objective To examine miR‐146a and miR‐218 expression patterns in cervical cancer, and to determine their value as biomarkers for cervical cancer. Methods Cervical cancer tissue microarray (TMA) samples (BioGenex TS‐4215) were used in this study. Probes for miR‐146a and miR‐218 were labeled with 5’‐Fluorescein. Fully automated Xmatrx system (from slides baking, denaturation, hybridization, detection, and final coversliping) was used for the experiments. Results Among the 33 cervical cancer TMA samples, upregulated cytoplasmic expression of miR‐146a in cancer cells was observed in 22 tissue samples (66.7%). There were 11 cervical cancer samples that exhibited basal level expression (33.3%). Only 8 out of 33 cervical cancer samples demonstrated elevated levels of miR‐218 (24.2%), 19/33 (58%) showed basal level expression, and there were 6/33 samples (18%) displayed low expression level. Conclusions miR‐146a expression is upregulated in cervical cancer. This may be used as a biomarker for the molecular diagnosis of cervical cancer. Future determination of the expression level and clinical prognosis is of importance for developing miR‐146a as a potential novel therapeutic agent against cervical cancer. (Supported by BioGenex Laboratories)